Stratec SE Stock
€27.25
Your prediction
Stratec SE Stock
Pros and Cons of Stratec SE in the next few years
Pros
Cons
Performance of Stratec SE vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stratec SE | 1.120% | -8.503% | 0.373% | -29.304% | -10.184% | -70.472% | -72.211% |
| Paul Hartmann AG | -0.820% | 0.000% | 0.000% | 26.234% | 8.969% | -17.065% | -24.063% |
| Eckert & Ziegler Strahlen- und Medizintechnik AG | 1.440% | -6.170% | -6.029% | 50.750% | 40.302% | 37.214% | 48.100% |
| Geratherm Medical AG | 1.280% | -3.096% | -3.988% | -17.632% | -10.057% | -59.456% | -69.904% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Stratec, a company operating in the Healthcare Equipment & Supplies industry, present a mixed picture. On one hand, the firm exhibits solid revenue generation capabilities and figures that suggest a growing market presence. On the other hand, certain financial metrics raise concerns about its profit margins and growth potential. A careful examination of the balance sheet, cash flow statements, income statements, and financial ratios reveals both strengths and weaknesses.
*Pros: *
Strong Revenue Generation: Stratec reported a total revenue of €261.91 million in 2023, with a consistent upward trend observed over the previous years. This reflects the company’s capacity to capture market share and expand its operations in a growing healthcare sector.
Comments
News
EQS-News: STRATEC ANNUAL GENERAL MEETING APPROVES DIVIDEND DISTRIBUTION OF € 0.60 PER SHARE
EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2025
EQS-News: STRATEC REPORTS RESULTS FOR 2024 FINANCIAL YEAR